Antipsychotic Drugs

Correct Answer

B — Aripiprazole

Rationale

Aripiprazole has one of the broadest Food and Drug Administration-approved indication ranges of any antipsychotic. Beyond schizophrenia and bipolar I disorder mania, it is approved as adjunctive therapy in major depressive disorder, for irritability associated with autistic disorder, and for Tourette syndrome. Brexpiprazole is also approved as an adjunct in major depressive disorder, but the question asks which agent holds this indication alongside schizophrenia and bipolar mania — a combination that matches aripiprazole specifically. Cariprazine is approved for schizophrenia, bipolar mania, and bipolar depression. Ziprasidone is approved for schizophrenia and bipolar mania but not for major depressive disorder adjunct therapy.

Correct Answer

D — Cariprazine

Rationale

Cariprazine is classified as a D3-preferential partial agonist, with a dopamine D3 to D2 affinity ratio of approximately 10 to 1 — making it the most D3-selective compound among currently approved antipsychotics. This D3 preference distinguishes cariprazine pharmacologically from aripiprazole and brexpiprazole, which have comparable affinity at D2 and D3 receptors. The D3 receptor is concentrated in limbic structures associated with motivational and reward processing, which is the pharmacological basis for cariprazine's clinical evidence in the negative symptom domain of schizophrenia. Lurasidone is a full D2 antagonist, not a partial agonist, and does not share this D3-preferential profile.

Correct Answer

A — Ziprasidone

Rationale

Ziprasidone produces mean QTc interval prolongation of approximately 10 milliseconds at standard doses — greater than most other second-generation antipsychotics, though substantially less than thioridazine. Because of this QTc effect, a baseline electrocardiogram is recommended before starting ziprasidone, and the drug is contraindicated in patients with a history of QTc prolongation, congenital long QT syndrome, or those taking other QTc-prolonging agents. Lurasidone does not prolong the QTc interval to a clinically meaningful degree and does not carry this baseline electrocardiogram requirement. Aripiprazole and cariprazine are partial D2 agonists with negligible QTc effects and no electrocardiogram monitoring requirement before initiation.

Correct Answer

C — Asenapine

Rationale

Asenapine's oral bioavailability is negligible when swallowed because of extensive first-pass hepatic metabolism. It must be placed under the tongue and allowed to dissolve completely — sublingual absorption through the buccal mucosa yields approximately 35 percent bioavailability. Patients must not eat or drink for 10 minutes after sublingual dosing. Failure to follow this consistently results in therapeutic failure that may be misattributed to treatment resistance. A transdermal patch formulation is also approved for patients with adherence challenges related to the sublingual requirement. Ziprasidone and lurasidone are administered orally and require food co-administration for adequate bioavailability, but they are swallowed tablets, not sublingual preparations. Iloperidone is also an oral tablet requiring slow titration for orthostatic hypotension, not a sublingual agent.

Correct Answer

B — Lurasidone

Rationale

Lurasidone has the most extensively developed evidence base for bipolar depression of any agent in this module and is Food and Drug Administration-approved for bipolar depression as both monotherapy and as adjunctive therapy with lithium or valproate. Its favorable metabolic profile — minimal weight gain and no clinically meaningful QTc prolongation — makes it a practical long-term choice in bipolar patients where metabolic management is a priority. Aripiprazole is approved for bipolar mania but not specifically for bipolar depression monotherapy. Ziprasidone is approved for schizophrenia and bipolar mania but lacks a bipolar depression indication. Asenapine is approved for schizophrenia and bipolar I mania.

Correct Answer

D — Iloperidone

Rationale

Iloperidone requires a mandatory 7-day dose titration before reaching the target therapeutic dose. The approved initiation protocol starts at 1 milligram twice daily and increases by 2 milligrams per day in increments over 7 days. This slow titration is required because iloperidone's pronounced alpha-1 adrenergic blockade — among the most significant of any second-generation antipsychotic — produces severe orthostatic hypotension and syncope if the dose is escalated too rapidly. Failure to follow this titration schedule is associated with falls and symptomatic hypotension. Lurasidone, cariprazine, and aripiprazole do not require mandatory slow titration protocols before reaching therapeutic doses, though gradual initiation is generally advisable for any antipsychotic to allow tolerability assessment.

Correct Answer

C — Partial D2 agonists provide enough residual D2 receptor activation in the tuberoinfundibular pathway to maintain partial dopaminergic inhibition of prolactin secretion

Rationale

Dopamine normally inhibits prolactin secretion from pituitary lactotroph cells by activating D2 receptors in the tuberoinfundibular pathway. Full D2 antagonists block these receptors completely, eliminating all dopaminergic inhibition and allowing prolactin to rise without restraint — producing hyperprolactinemia. Partial D2 agonists occupy the same D2 receptors but activate them to an intermediate degree. Because partial agonist activation is greater than zero, partial inhibition of prolactin secretion is maintained in the tuberoinfundibular pathway, and prolactin elevation is minimal to none. This explains why aripiprazole, brexpiprazole, and cariprazine have negligible effects on prolactin at therapeutic doses, while risperidone and haloperidol produce sustained, clinically significant hyperprolactinemia. Partial agonists do not achieve pathway-selective D2 blockade — they reach the tuberoinfundibular pathway just as full antagonists do, but their partial activation at that site preserves dopaminergic tone rather than eliminating it.

Correct Answer

A — Reduce aripiprazole dose to 25 percent of the original — both metabolic pathways are inhibited simultaneously, eliminating compensatory clearance through either route

Rationale

Aripiprazole's dual cytochrome P450 2D6 and cytochrome P450 3A4 metabolism creates an additive interaction risk. When only one pathway is inhibited — either cytochrome P450 2D6 or cytochrome P450 3A4 alone — the other pathway partially compensates for the reduced clearance, and a 50 percent dose reduction is sufficient. When both pathways are inhibited simultaneously, as in this patient receiving fluoxetine and ketoconazole together, compensatory clearance through either route is eliminated and aripiprazole plasma levels can rise substantially — requiring dose reduction to 25 percent of the original dose. Brexpiprazole follows the same dual-pathway rules. This additive interaction principle reflects a general pharmacokinetic principle for drugs with multiple clearance pathways: simultaneous inhibition of all major pathways produces a multiplicative rather than merely additive effect on drug exposure.

Correct Answer

D — Cariprazine has a major active metabolite with a half-life of 1 to 3 weeks that accumulates during treatment and continues to exert pharmacological effects for weeks after the parent drug is stopped

Rationale

Cariprazine's parent drug has a half-life of 2 to 4 days, which would predict a washout within roughly one to two weeks. However, cariprazine is converted to didesmethyl-cariprazine, an active metabolite that shares its receptor pharmacology and has a half-life of 1 to 3 weeks. During ongoing treatment, didesmethyl-cariprazine accumulates substantially and reaches full steady state over 4 to 8 weeks. When cariprazine is discontinued, the parent drug clears relatively quickly, but didesmethyl-cariprazine continues to exert pharmacological effects — including akathisia — for weeks afterward. This prolonged effective duration is clinically important: patients and clinicians should not expect rapid resolution of cariprazine-related adverse effects after stopping the drug, and dose reductions are often preferable to abrupt discontinuation when adverse effects emerge at higher doses. This pharmacokinetic profile also means that full cariprazine steady state and clinical effect may not be achieved for 4 to 8 weeks after initiation — longer than most other antipsychotics.

Correct Answer

B — Ziprasidone's oral bioavailability approximately doubles when taken with food — without food, the patient receives substantially lower plasma levels than the prescribed dose implies

Rationale

Ziprasidone has a pharmacokinetic food dependency that is not merely a clinical recommendation but a functional requirement for adequate drug exposure. When taken with a meal providing at least 500 calories, ziprasidone's oral bioavailability approximately doubles compared with fasting. A patient who consistently takes ziprasidone without food is effectively receiving a substantially lower dose than prescribed — potentially insufficient for antipsychotic effect. Before concluding that the prescribed dose is inadequate and escalating, the clinician must assess and correct food adherence. This is the pharmacokinetically correct first step in apparent ziprasidone non-response. Lurasidone has a similar food dependency — its bioavailability approximately triples with at least 350 calories compared with fasting. Every patient on either agent must be explicitly instructed to take the drug with food at every dose and reassessed for food adherence at every visit.

Correct Answer

C — Because lurasidone has no alternative metabolic pathway, strong inhibitors raise plasma levels to potentially toxic concentrations and strong inducers may render the drug completely subtherapeutic — a magnitude of change too large to reliably manage with dose modification

Rationale

When a drug is metabolized by a single enzyme, blocking that enzyme produces the maximum possible pharmacokinetic interaction — there is no alternative clearance pathway to provide compensatory elimination. For lurasidone, strong cytochrome P450 3A4 inhibitors such as ketoconazole, clarithromycin, and ritonavir can raise lurasidone plasma levels to concentrations that may produce toxicity, and no dose reduction can reliably predict a safe level across different inhibitors and individual patients. Strong cytochrome P450 3A4 inducers such as carbamazepine, rifampin, and St. John's Wort can reduce lurasidone levels so dramatically that the drug may become completely ineffective at any practical dose. The contrast with quetiapine — which is also primarily cytochrome P450 3A4 dependent — is instructive: for quetiapine, strong inhibitors require dose reduction to approximately one-sixth, but dose adjustment is considered manageable. For lurasidone, the interaction magnitude is judged sufficient to classify strong interactors as contraindications rather than adjustment situations.

Correct Answer

A — Cariprazine's preferential D3 receptor affinity targets limbic circuits involved in motivation and reward, which are the neural substrate of avolition and anhedonia in schizophrenia

Rationale

Cariprazine's D3 to D2 receptor affinity ratio of approximately 10 to 1 makes it the most D3-selective antipsychotic currently approved. Dopamine D3 receptors are concentrated in limbic brain regions — particularly the nucleus accumbens and ventral striatum — that are central to motivational processing and reward signaling. Avolition and anhedonia, the motivational and hedonic components of negative symptoms, are thought to arise from dysfunction in these circuits. By preferentially engaging D3 receptors in these limbic structures, cariprazine addresses the neurobiological substrate of negative symptoms more directly than agents whose pharmacological activity is dominated by D2 receptor interactions in the dorsal striatum. The Nemeth 2017 Lancet trial, which compared cariprazine against risperidone specifically in patients with predominant negative symptoms over 26 weeks, provided the strongest clinical evidence for any approved antipsychotic specifically targeting this symptom domain.

Correct Answer

D — Lower D2 intrinsic efficacy than aripiprazole, designed to reduce akathisia; more pronounced alpha-1 adrenergic antagonism, producing greater orthostatic hypotension during initiation

Rationale

Brexpiprazole was developed after aripiprazole with two specific receptor modifications. First, its D2 intrinsic efficacy is lower — approximately 20 percent relative to full dopamine activation compared with aripiprazole's 25 to 30 percent. Because akathisia in partial agonists may be related to the degree of D2 activation in certain circuits, this lower intrinsic efficacy was designed to reduce akathisia rates. Clinical trial data suggest numerically lower akathisia with brexpiprazole compared with aripiprazole, though the difference is modest and individual predictors remain unclear. Second, brexpiprazole has more pronounced alpha-1 adrenergic antagonism than aripiprazole. While this alpha-1 activity may contribute to mood-stabilizing effects, it produces greater orthostatic hypotension during initiation — requiring gradual dose titration, particularly in elderly patients. Both agents share the same cytochrome P450 2D6 and cytochrome P450 3A4 dual-pathway metabolism and the same dosing interaction rules.

Correct Answer

B — Partial D2 agonists maintain residual D2 receptor activation in the nigrostriatal pathway, stabilizing rather than depleting dopamine tone and preserving motor circuit function

Rationale

Full D2 antagonists such as haloperidol or risperidone completely block nigrostriatal D2 receptors, eliminating dopaminergic tone in the striatal motor circuits and producing the drug-induced parkinsonism, dystonia, and akathisia that collectively constitute extrapyramidal symptoms. Partial D2 agonists such as aripiprazole, brexpiprazole, and cariprazine occupy the same nigrostriatal D2 receptors but activate them to an intermediate degree. This partial activation maintains some residual dopamine signaling in the motor circuits — enough to preserve baseline striatal function — rather than depleting it to zero as full antagonists do. The result is a stabilization of dopamine tone that substantially reduces extrapyramidal symptom risk. Partial agonists do not achieve pathway-selective D2 blockade; they reach the nigrostriatal pathway just as full antagonists do, but their partial activation at that site prevents the motor side effects that complete blockade produces. They also do not have inherent anticholinergic activity as part of their mechanism of action.

Correct Answer

D — Clarithromycin inhibits cytochrome P450 3A4, the only metabolic pathway for lurasidone, causing a large rise in lurasidone plasma levels and drug excess at the previously well-tolerated dose

Rationale

Lurasidone is exclusively metabolized by cytochrome P450 3A4, with no alternative clearance pathway. Clarithromycin is a strong cytochrome P450 3A4 inhibitor. When clarithromycin is added to stable lurasidone therapy, hepatic metabolism of lurasidone is substantially blocked and plasma levels rise to potentially toxic concentrations — producing drug excess that manifests as severe sedation, orthostatic hypotension, and cognitive impairment at the previously well-tolerated dose. This combination is classified as an absolute contraindication, not simply a dose-adjustment situation, because the magnitude of level increase from single-enzyme blockade with no compensatory pathway is too large to reliably manage with dose reduction alone. When this patient requires an antibiotic for respiratory infection, a macrolide antibiotic such as clarithromycin should be avoided in favor of an alternative that does not inhibit cytochrome P450 3A4. The interaction illustrates why exclusive single-enzyme dependence creates qualitatively different pharmacokinetic risk compared with dual-pathway agents such as aripiprazole.

Correct Answer

A — Ziprasidone's oral bioavailability approximately doubles when taken with food — consistently taking it without food results in plasma levels substantially below those achieved at the prescribed dose with adequate caloric intake

Rationale

Ziprasidone has a well-documented pharmacokinetic food dependency: oral bioavailability approximately doubles when the drug is taken with a meal providing at least 500 calories, compared with fasting. A patient who consistently takes ziprasidone without food is receiving a functionally subtherapeutic dose — the milligram amount prescribed may be adequate, but the actual drug exposure achieved in the fasting state is substantially lower than intended. Before concluding that the dose needs to be increased, the clinician must correct the food adherence pattern. This is a pharmacokinetic issue that is entirely correctable without changing the prescription. Lurasidone has a similar but more pronounced food dependency — its bioavailability approximately triples with at least 350 calories. These food requirements must be communicated explicitly and reinforced at every clinical contact for patients on either agent.

Correct Answer

C — Cariprazine's major active metabolite has a half-life of 1 to 3 weeks and continues to exert pharmacological effects, including akathisia, for weeks after the parent drug is stopped

Rationale

Cariprazine is converted to didesmethyl-cariprazine, an active metabolite that shares its receptor pharmacology and accumulates substantially during treatment. The half-life of didesmethyl-cariprazine is 1 to 3 weeks — far longer than the parent compound's 2 to 4 day half-life. When cariprazine is discontinued, the parent drug clears within approximately one to two weeks, but didesmethyl-cariprazine continues to occupy D2 and D3 receptors and to produce pharmacological effects — including akathisia — for weeks afterward. A clinician who expects rapid resolution of cariprazine-related adverse effects after stopping the drug will be misled by the persistent pharmacology of this long-lived metabolite. This is a clinically important pharmacokinetic property: when cariprazine is stopped due to intolerable adverse effects, patients and clinicians should be explicitly counseled to expect slow resolution rather than rapid washout. The same prolonged effective duration also means that full clinical benefit from cariprazine may not be apparent for 4 to 8 weeks after initiation.

Correct Answer

B — Cariprazine — its D3-preferential partial agonism targets limbic motivational circuits, and a randomized trial demonstrated superiority over risperidone specifically for predominant negative symptoms

Rationale

Cariprazine is the appropriate choice for this patient based on two converging considerations. First, its D3 to D2 receptor affinity ratio of approximately 10 to 1 preferentially engages dopamine D3 receptors in limbic structures — including the nucleus accumbens — that are central to motivational and reward processing. This receptor profile directly targets the neural circuits underlying avolition and anhedonia. Second, cariprazine has the strongest clinical evidence of any currently approved antipsychotic for primary negative symptoms: a prospective randomized Lancet trial comparing cariprazine against risperidone specifically in patients with predominant negative symptoms demonstrated superior improvement in negative symptom scores with cariprazine at all assessment points over 26 weeks. No other currently approved antipsychotic has Class I evidence for a primary negative symptom endpoint. While ziprasidone, aripiprazole, and lurasidone each have pharmacological properties that may offer some secondary benefit for negative symptoms, none has trial evidence in a population selected specifically for predominant negative symptoms.